Signaling to the mechanistic target of rapamycin (mTOR) regulates diverse cellular processes, including protein translation, cellular proliferation, metabolism, and autophagy. Most models place Akt upstream of the mTOR complex, mTORC1; however, in T cells, Akt may not be necessary for mTORC1 activation. We found that the adaptor protein Carma1 [caspase recruitment domain (CARD)-containing membrane-associated protein 1] and at least one of its associated proteins, the paracaspase MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1), were required for optimal activation of mTOR in T cells in response to stimulation of the T cell receptor (TCR) and the co-receptor CD28. However, Bcl10, which binds to Carma1 and MALT1 to form a complex that mediates signals from the TCR to the transcription factor NF-kB (nuclear factor kB), was not required. The catalytic activity of MALT1 was required for the proliferation of stimulated CD4 + T cells, but not for early TCR-dependent activation events. Consistent with an effect on mTOR, MALT1 activity was required for the increased metabolic flux in activated CD4 + T cells. Together, our data suggest that Carma1 and MALT1 play previously unappreciated roles in the activation of mTOR signaling in T cells after engagement of the TCR.
INTRODUCTION
Upon stimulation with antigen, naïve T cells rapidly proliferate, produce cytokines, and migrate from lymphoid organs, after which they mediate diverse effector functions in tissues. Dysregulation of T cell signaling events is associated with autoimmune diseases and lymphomas; thus, dissection of the mechanisms leading to T cell activation may lead to more efficacious therapies. Signaling events initiated by receptors for antigens, growth factors, and cytokines lead to activation of the serine and threonine kinases phosphatidylinositol 3-kinase (PI3K), Akt, and mechanistic target of rapamycin (mTOR), to regulate cellular growth and proliferation (1, 2) . The 70-kD ribosomal protein S6 kinase (p70S6K), which directly phosphorylates ribosomal protein S6, is a key effector of mTOR (3) . S6 is a critical regulator of protein translation because it is necessary for ribosome biogenesis, and is thus an indirect regulator of cellular proliferation (4) . Another important substrate of mTOR is the translational inhibitor eukaryotic initiation factor 4E (eIF4E)-binding protein 1 (4E-BP1), phosphorylation of which releases its inhibition of the translation of certain mRNAs (2) .
In T cells, engagement of the T cell receptor (TCR) and the costimulatory receptor CD28 stimulates activation of PI3K and Akt, which leads to the activation of mTOR, p70S6K, and S6 (5, 6) . Investigation of the specific roles of S6K and S6 in the activation of T cells has revealed a requirement for these proteins in cellular proliferation. Notably, heterozygous expression of Rps6 (the gene encoding S6) limits T cell proliferation in response to stimulation of the TCR, without having any effect on changes in cellular size or on early activation events (7) . Akt is a central modulator of T cell signaling pathways that control metabolism, growth, migration, and activation (8) (9) (10) . However, a study has suggested that the phosphorylation of S6 downstream of the TCR and CD28 is not strictly dependent on Akt (11) .
Caspase recruitment domain (CARD)-containing membrane-associated protein 1 (Carma1) is an adaptor protein, predominantly found in lymphocytes, that interacts with B cell lymphoma 10 (Bcl10) and mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) upon antigen receptor stimulation to form the Carma1, Bcl10, and MALT1 (CBM) complex. This protein complex is necessary for optimal activation of the nuclear factor kB (NF-kB) and c-Jun N-terminal kinase (JNK) signaling pathways in response to TCR stimulation (12) (13) (14) (15) . In addition, both Carma1 and MALT1 act as tumor-promoting proteins in diffuse large B cell lymphoma (DLBCL) (16) (17) (18) (19) . Studies of the molecular mechanisms by which MALT1 regulates T cell activation have revealed it as a paracaspase (20) (21) (22) . Thus, inhibition of the catalytic activity of MALT1 with the selective inhibitor z-VRPR-fmk leads to partially impaired activation of NF-kB (21) .
We have demonstrated previously uncharacterized roles for Carma1 and MALT1 in the activation of T cells, specifically through a signaling pathway leading to the activation of mTORC1. Loss of Carma1 or MALT1 impaired the TCR-and CD28-dependent phosphorylation of S6, as well as of another downstream target of mTOR, 4E-BP1. In contrast, loss of the Carma1-and MALT1-associated protein Bcl10 had no discernible effect on mTORC1 activation. Furthermore, the MALT1 inhibitor z-VRPR-fmk inhibited both the phosphorylation of S6 and the proliferation of primary CD4 + T cells in response to stimulation of the TCR and CD28. Inhibition of MALT1 activity also impaired the ability of activated T cells to increase their metabolic output, which is largely dependent on the mTOR pathway (23, 24) . Thus, our studies have revealed the existence of a previously unappreciated connection between Carma1, MALT1, and mTORC1, which leads to enhanced T cell proliferation and metabolism.
To understand other possible downstream effectors of Akt and Carma1, we compared the phosphorylation of potential Akt substrates between the parental human Jurkat T cell lymphoma cell line and a variant cell line lacking Carma1: JPM 50.6 cells (26) . We stimulated Jurkat cells, JPM 50.6 cells, and JPM 50.6 cells transfected with plasmid encoding Carma1 (Carma1-reconstituted JPM 50.6 cells) with antibodies against CD3 and CD28. Through Western blotting analysis with an antibody that recognizes phosphorylated substrates of Akt, we detected a prominent band of about 30 kD with differing patterns of phosphorylation between Jurkat, JPM 50.6, and Carma1-reconstituted JPM 50.6 cells (Fig. 1A) . The activation of Akt is normal in JPM 50.6 cells, including both the phosphorylation of Thr 308 (T308) and Ser 473 (S473) and its catalytic activity, as shown by us and others (25, 26) .
Akt is a member of the large class of AGC kinases, and as such, it shares at least partial substrate specificity (RxRxxS/T) with these kinases, notably the protein kinase p70S6K (R/KxRxxS/T) (27) . On the basis of the mobility of the 30-kD band that we detected (Fig. 1A) , we hypothesized that it might be the ribosomal protein S6, a prominent substrate for p70S6K and a downstream effector of the mTOR pathway, that is activated by growth factor or TCR signaling (28) . Thus, we directly assessed the activation of S6 induced by the TCR and costimulatory molecules through its phosphorylation at Ser 235 and Ser 236 (S235/236). Through Western blotting analysis with a phospho-specific antibody, we observed the impaired induction of S6 phosphorylation in Carma1-deficient JPM 50.6 cells compared with that in transfected JPM 50.6 cells reconstituted with Carma1 (Fig. 1B) . We also observed this defect when S6 phosphorylation was assessed by intracellular phospho-flow cytometry (Fig. 1C , middle panel). However, phosphorylation of S6 in response to amino acids, which proceeds through a distinct pathway (29) , was intact in JPM 50.6 cells (Fig. 1C, right panel) , indicating that the S6 phosphorylation defect in these cells is relatively specific. We also observed apparently identical amounts of total S6 protein in JPM 50.6 cells and Jurkat cells ( fig. S1A) .
Next, we examined the phosphorylation of S6 at an additional cluster of residues, Ser 240 and Ser 244 (S240/244), another established readout for S6 activation (4) . Again, we observed decreased S6 phosphorylation at these sites in JPM 50.6 cells compared with that in the parental Jurkat cells ( fig. S1 , B and C). For reasons that are unclear, we sometimes observed increased basal phosphorylation of S6 in the JPM 50.6 cells (Fig. 1, B and  D) . Thus, the cellular response to amino acid concentrations, which also results in S6K activation and S6 phosphorylation, does not require Carma1. These data suggest that regulation of S6 by Carma1 may be relatively receptor-or cell type-specific. JPM 50.6 cells were originally derived by chemical mutagenesis of Jurkat cells (26) . To further validate the results obtained with these cells, we specifically knocked down Carma1 in Jurkat cells by transducing the cells with lentivirus encoding Carma1-specific short hairpin RNA (shRNA). We then analyzed the phosphorylation of S6 after stimulation of both the parental Jurkat cells and the Carma1 knockdown cells (Carma1shRNA cells) with antibodies against CD3 and CD28. Similar to results obtained with JPM 50.6 cells, we found that the abundance of phosphorylated S6 (pS6) in Carma1shRNA cells was reduced compared to that in parental Jurkat cells transduced with lentivirus encoding control shRNA (Fig. 1D  and fig. S1D ). To further confirm our findings in primary T cells, we assessed S6 phosphorylation after the stimulation of naïve T cells from wildtype and Carma1 knockout (KO) mice with phorbol 12-myristate 13-acetate (PMA) and ionomycin (30, 31) . Consistent with the results obtained from our earlier experiments with cell lines, we observed impaired induction of S6 phosphorylation in the Carma1 KO T cells (Fig. 1E) . Together, these data suggest that Carma1 has a previously unrecognized role in TCR signaling events that lead to the phosphorylation of ribosomal protein S6.
Carma1 promotes p70S6K activation and 4E-BP1 phosphorylation
To better define the role of Carma1 in mediating phosphorylation of S6 and associated pathways, we assessed the activity of the kinase immediately upstream of S6, p70S6K (S6K). After engagement of TCR and CD28, p70S6K becomes activated and phosphorylates S6, which leads to increased ribosome biogenesis (32) . We found that the extent of p70S6K phosphorylation in stimulated JPM 50.6 cells was reduced compared to that in stimulated Carma1-reconstituted JPM 50.6 cells ( Fig. 2A) . Additionally, we performed in vitro kinase assays with p70S6K isolated from either Jurkat cells or JPM 50.6 cells, together with glutathione S-transferase (GST)-tagged S6 (GST-S6) as a substrate. We observed an increase in p70S6K catalytic activity after stimulation of the parental Jurkat cells, but not Carma1-deficient JPM 50.6 cells (Fig. 2B) . Because p70S6K activity can be enhanced by mTOR (33, 34) , we decided to investigate this pathway in more detail.
Our initial experiments suggested that activation-associated phosphorylation of mTOR in Jurkat cells and JPM 50.6 cells was similar, although we could only ever achieve modest, if any, inducible phosphorylation of mTOR by stimulation with antibodies against CD3 and CD28 ( fig. S2A ). We also assessed tuberous sclerosis 2 (TSC2), which lies upstream of mTOR, and observed a modest, and inconsistent, stimulation-dependent increase in TSC2 phosphorylation in both JPM 50.6 cells and Carma1-reconstituted JPM 50.6 cells ( fig. S2B ). We next sought to determine whether other downstream effectors of mTOR, for example, 4E-BP1, were regulated by Carma1. Investigation of this pathway in JPM 50.6 cells revealed that these cells had no detectable 4E-BP1 protein, nor did they have mRNA encoding 4E-BP1 ( fig. S2, C and D) . Thus, we used the Carma1shRNA cells described earlier to determine a possible role for Carma1 in the regulation of 4E-BP1. We observed that the abundance of phosphorylated 4E-BP1 protein in stimulated Carma1shRNA cells was substantially reduced compared to that in control Jurkat cells, despite both cell types having apparently similar amounts of total 4E-BP1 protein (Fig. 2, C and D) . These results suggest that Carma1 also plays a role in the regulation of mTOR activation, upstream of S6K, S6, and 4E-BP1.
Protein kinase C activity promotes S6 activation in T cells
Carma1 is "activated" through phosphorylation of its linker domain by multiple isoforms of protein kinase C (PKC), among other kinases (35) . To assess whether PKC-mediated phosphorylation of Carma1 might play a role in the TCR-and CD28-dependent phosphorylation of S6, we used the well-characterized PKC inhibitor bisindolylmaleimide VIII acetate (BIM; fig. S3A ). We also used an allosteric Akt-specific inhibitor, Akti1/2 (36) , to determine the relative role of Akt in this pathway ( fig. S3A ). We observed that the TCR-and CD28-dependent phosphorylation of S6 was partially impaired in D10 cells [a mouse T helper 2 (T H 2) cell line] after these cells were pretreated with BIM or Akti1/2 (Fig. 3A) . The latter result is consistent with a report from Macintyre et al. (11) , who used CD8 + effector T cells. Further analysis of the PKC-mediated activation of S6 showed that BIM inhibited S6 phosphorylation in stimulated mouse primary CD4 + T cells (Fig.  3B ). To assess a potential requirement for Carma1 in the PKC-mediated phosphorylation of S6, we performed experiments with Jurkat cells or JPM 50.6 cells pretreated with varying concentrations of BIM. Whereas S6 phosphorylation in parental Jurkat cells was sensitive to BIM, the residual S6 phosphorylation seen in JPM 50.6 cells was refractory to further inhibition by BIM (Fig. 3C) . These results are consistent with the existence of a signaling pathway from TCR-mediated activation of PKC to Carma1 and S6 phosphorylation.
MALT1, but not Bcl10, mediates the TCR-and CD28-dependent activation of mTOR signaling Activation of NF-kB by Carma1 is mediated by at least two other proteins: Bcl10 and MALT1 (37) . After engagement of the TCR and CD28, these proteins associate with each other to form the CBM complex, in which they function to activate downstream effectors, including the inhibitor of kB (IkB) kinase (IKK) complex (38) . Thus, we sought to determine whether MALT1 and Bcl10 also played roles in the activation of S6 in experiments with previously described T cell lines that have reduced amounts of Bcl10 or MALT1 as a result of the expression of specific shRNAs ( Fig. 4A) phosphorylation of S6 after the TCR-and CD28-dependent stimulation of MALT1shRNA cells compared with that in Bcl10shRNA cells (Fig. 4 , B to D). Because of the lack of an apparent effect of loss of Bcl10 on S6 phosphorylation, we next stimulated CD4 + T cells isolated from wild-type and Bcl10 KO mice and found that both sets of cells were indistinguishable in their ability to induce S6 phosphorylation in response to stimulation (Fig. 4E ).
To further investigate a possible requirement for MALT1 in mTOR activation, we also assessed the extent of 4E-BP1 phosphorylation in MALT1shRNA cells. Similar to the phenotype observed in Carma1shRNA cells, 4E-BP1 phosphorylation in cells with reduced MALT1 abundance was substantially reduced compared to that in control Jurkat cells (Fig. 4F and fig. S3B ). That S6 phosphorylation was normal in Jurkat cells lacking Bcl10 suggests that the impairment in S6 phosphorylation in Carma1-deficient T cells was not merely a result of dysregulated NF-kB activity. Nonetheless, we confirmed this more directly by assessing the effect of a small-molecule inhibitor of IKK on S6 phosphorylation. As expected, this compound inhibited the activation of an NF-kB reporter in T cells ( fig. S3C ), but it had no effect on the CD3-and CD28-dependent phosphorylation of S6 in primary T cells (Fig. 4G ), indicating that this previously unappreciated pathway was indeed independent of IKK signaling. Thus, these results suggest that whereas MALT1, like Carma1, is required for the optimal phosphorylation of mTOR substrates downstream of TCR and CD28 signaling, Bcl10 does not play as critical a role in this pathway.
To further define the relationship between MALT1 and mTOR-p70S6K signaling, we investigated whether these proteins might be present together in a biochemical complex. We immunoprecipitated MALT1 from T cell lysates and analyzed samples by Western blotting for the presence of p70S6K; MALT1shRNA cells subjected to immunoprecipitation with an antibody against MALT1 served as a negative control. Thus, we observed an association between MALT1 and p70S6K in Jurkat cells, which did not seem to depend on stimulation with antibodies against CD3 and CD28 (Fig. 4H , left). We were also able to detect the presence of mTOR in a complex with MALT1 ( Fig. 4H , right). It is still unclear whether any of these interactions is direct; however, formation of this complex appears to occur independently of TCR signaling, at least in Jurkat cells.
The catalytic activity of MALT1 is required for S6 phosphorylation and cellular proliferation in T cells, but not for early activation events Selective inhibition of the paracaspase activity of MALT1 with the compound z-VRPR-fmk partially inhibits the activation of NF-kB and retards the growth of activated B cell-like DLBCL cell lines (40) . Consistent with earlier studies, we confirmed that this inhibitor partially prevented the TCR-and CD28-dependent, but not the tumor necrosis factor (TNF)-dependent, activation of an NF-kB reporter ( fig. S4A ). In addition, z-VRPR-fmk had no effect on the phosphorylation of extracellular signalregulated kinase (ERK) (fig. S4B) ; however, pretreatment of Jurkat cells with z-VRPR-fmk impaired the activation of the mTOR pathway, as revealed by decreased S6 phosphorylation (Fig. 5A) . These results were recapitulated in experiments with primary murine CD4 + T cells, in which pretreatment with z-VRPR-fmk substantially inhibited the anti-CD3-and anti-CD28-dependent phosphorylation of S6 (Fig. 5B) . As an additional control for specificity, we also assessed whether z-VRPR-fmk had any effects in MALT1-deficient T cells. Thus, we found that the residual S6 phosphorylation observed in MALT1-deficient T cells was not affected by z-VRPR-fmk ( fig. S4C ). We also assessed the effects of the MALT1 inhibitor at later time points, and found that z-VRPR-fmk-treated primary CD4 + T cells still had substantially impaired S6 phosphorylation up to 72 hours after stimulation with antibodies against CD3 and CD28 (Fig. 5C) . These results suggest a specific role for the catalytic activity of MALT1, in addition to its presence, in promoting mTOR activation in T cells.
Previous studies on the functions of Carma1, Bcl10, and MALT1 in T cell activation have predominantly focused on regulation of the transcription factor NF-kB (26, 37, 41) . Because our data indicated a requirement for Carma1 and MALT1 for optimal mTOR activation upon T cell stimulation, we next sought to investigate the functional consequences of this pathway. Heterozygous expression of Rps6 (the gene encoding ribosomal protein S6) results in the impaired proliferation of T cells, but not in the acute increase in cell size ("blasting") that follows T cell activation (7) . On the basis of the role of MALT1 in S6 phosphorylation that we uncovered, we hypothesized that treatment of naïve T cells with the MALT1 inhibitor might phenocopy the effects of reduced S6 abundance on T cell proliferation. We pretreated naïve CD4 + T cells with z-VRPR-fmk and then stimulated them with antibodies against CD3 and CD28 for up to 72 hours before assessing cell number, cell size, and activation markers. As we expected, there was an initial decrease in T cell numbers, as a result of the cell death induced by the strong polyclonal anti-CD3 stimulation (Fig. 6A ). Although this trend was eventually reversed by 72 hours in the vehicletreated T cells, because of T cell proliferation, this reversal was not observed in cells treated with z-VRPR-fmk.
We also assessed the effects of z-VRPR-fmk on T cell proliferation more directly, using an assay that measures reduction of the dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). For these experiments, T cell stimulation was performed in the presence of exogenous IL-2 to ensure that the reduction in cell numbers was not a result of the reduced autocrine production of IL-2, as might be expected to happen because of the partial inhibition of NF-kB by z-VRPR-fmk. Thus, z-VRPRfmk substantially impaired the proliferation of primary CD4 + T cells, even in the presence of exogenous IL-2 (Fig. 6B) . Because IL-2 can also promote the phosphorylation of S6 through the mTOR pathway (42) , this suggests the existence of a nonredundant TCR-and CD28-dependent pathway that requires the catalytic activity of MALT1. Consistent with previous findings on the function of S6 (7), we saw that the decreased number of z-VRPR-fmk-treated cells was not reflected in altered T cell blasting. Thus, cell size, as measured by flow cytometric analysis of forward light scattering, was similar between vehicle-and inhibitor-treated T cells (Fig. 6C) . The initial activation of z-VRPR-fmk-treated T cells was comparable to that of vehicle-treated T cells, as determined by flow cytometric analysis of the abundance of the early activation marker CD69 (Fig.  6D) . Thus, our data suggest not only that Carma1 and MALT1 are required for the phosphorylation of S6 and its upstream regulator S6K but also that this pathway controls a known downstream target of S6 in T cells, namely, cellular proliferation, whereas it is dispensable for early activation events. before being subjected to immunoprecipitation (IP) with MALT1 antibody. Immunoprecipitates were then analyzed by Western blotting to detect MALT1-associated S6K (left) and mTOR (right). Blots are representative of three independent experiments. *P < 0.05, **P <0.01, by unpaired Student's t test.
T cells change from being quiescent to becoming activated (3, 23, 24).
Because our data revealed a role for MALT1 in the regulation of both proliferation and the mTOR pathway, we wanted to further assess the functional consequences of this effect. To this end, we assessed the extent of oxidative phosphorylation in CD4 + T cells stimulated overnight in the presence of the MALT1 inhibitor z-VRPR-fmk or the mTORC1 inhibitor rapamycin. These experiments were carried out in a Seahorse metabolic flux analyzer, which performs real-time measurements of oxidative phosphorylation and glycolysis. As expected, we observed a substantial increase in oxygen consumption in stimulated T cells compared with that in naïve T cells (Fig. 7A) . Treatment with z-VRPR-fmk or rapamycin inhibited the shift to increased metabolic activity (Fig. 7A ). This effect was apparent both in the basal state and after treatment with carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), an ionophore uncoupler that promotes the leakage of protons across the inner mitochondrial membrane and induces maximal oxygen consumption (Fig. 7A) . We also assessed the role of MALT1 in the increased extent of aerobic glycolysis, as determined by the extracellular acidification rate. As expected, stimulation of naïve T cells markedly increased the extent of glycolysis (Fig. 7B) . z-VRPR-fmk partially inhibited glycolysis in stimulated T cells, although not to the same extent as did rapamycin (Fig. 7B) ; however, this effect was not statistically significant. Increased cell surface abundance of the amino acid transporter CD98 and CD71 (transferrin receptor) in activated T cells is considered an mTOR-dependent event (45); however, we noted no difference in the abundances of these markers between z-VRPR-fmk-treated T cells and vehicle-treated T cells (fig. S4D) . Consistent with our earlier data, cells under all conditions exhibited similar cell surface amounts of CD69, indicative of the efficiency of early TCR-mediated activation, regardless of the presence of the MALT1 inhibitor (Fig. 7C) . Thus, inhibition of the protease activity of MALT1 had selective effects during the activation of naïve T cells, in particular on the metabolic reprogramming that is important for the proliferation of T cells.
DISCUSSION
It was previously thought that the phosphorylation of S6 downstream of activation of the TCR and CD28 proceeds exclusively through Akt, the TSC1-TSC2 complex, mTOR, and p70S6K (32), similar to the activation of S6 in other cell types, for example, in response to growth receptor stimulation. However, studies have introduced additional complexity to this simple linear model, specifically with regard to the requirement for Akt, as was demonstrated in experiments with CD8 + T cells (11) . Here, we revealed a previously unappreciated role for the proteins Carma1 and MALT1 in signaling upstream of mTOR, resulting in the phosphorylation of the ribosomal protein S6 and the translational regulator 4E-BP1 during T cell activation. This pathway appears to require PKC to a much greater extent than it requires Akt. Whereas we uncovered previously uncharacterized roles for Carma1 and MALT1, we found that Bcl10 was dispensable for S6 activation in T cells. Although most studies indicate that Carma1 and Bcl10 act in concert to mediate T cell activation, Carma1 also disassociates from Bcl10 and binds to other proteins, for example, the motor protein GAKIN (guanylate kinase-associated kinesin), upon TCR engagement (46) .
Our results suggest that Carma1 and MALT1 are also required for the phosphorylation of another target of mTOR signaling, 4E-BP1. Thus, we present a model whereby Carma1 and MALT1 mediate the activation of mTORC1 and its major downstream targets p70S6K and 4E-BP1 (Fig. 8) . We found that MALT1 physically associated with both p70S6K and mTOR, consistent with its apparent role in mediating this signaling pathway in T cells, although it is not clear whether either of these interactions is direct. Whereas mTOR is found in two distinct protein complexes (mTORC1 and mTORC2), we hypothesize that MALT1 specifically associates with and regulates mTORC1 because the phosphorylation of Akt at Ser 473 , a direct target of mTORC2, is normal in Carma1-deficient T cells (25, 26, 28) . Additionally, the phosphorylation of Akt at both Thr 308 and Ser
473
, as well as the phosphorylation by Akt of one of its direct targets, GSK-3b (glycogen synthase kinase 3b), is also normal in Carma1-deficient T cells (25, 26) . We propose a model whereby, upon stimulation of the TCR and CD28, Carma1 and MALT1 activate mTORC1 and its downstream targets S6 and 4E-BP1, and that this process occurs either downstream of or parallel to the Akt-dependent activation of mTORC1. Further study will be necessary to fully understand the underlying molecular mechanism(s) of this previously unappreciated pathway.
Given the known role of the CBM complex in the NF-kB pathway, we considered the possibility that impaired activation of mTOR in Carma1-or MALT1-deficient T cells (or in z-VRPR-fmk-treated T cells) might be a secondary effect of decreased NF-kB activity. However, a small-molecule IKK inhibitor did not impair S6 phosphorylation in stimulated primary CD4 + T cells, suggesting that the ability of Carma1 and MALT1 to mediate stimulation of p70S6K and S6 activity is independent of their roles in stimulating NF-kB activation. Regulation of NF-kB by the CBM complex also occurs in other cell types, for example, monocytes, in which the Carma1 homolog CARD9 promotes activation of NF-kB (47) . Knowing that these proteins have similar functions in other cell types, we are interested in determining whether they might also regulate activation of mTOR signaling.
We often noted increased basal phosphorylation of S6 in Carma1-deficient Jurkat T cells compared to that in the parental cell line, which may be a result of the persistent inhibition of basal S6-mediated protein translation, because this activates p70S6K and thus S6 (48) . Nonetheless, our use of extended nutrient starvation and investigation into additional S6 phosphorylation sites, including S240 and S244, which are indicative of activation ( fig. S1B ), confirmed our findings that Carma1 mediates the TCR-and CD28-dependent activation of mTOR. Furthermore, T cells from Carma1 KO mice did not exhibit increased basal S6 phosphorylation compared to that in wild-type cells (Fig. 1E) . Finally, treatment of primary T cells with the MALT1 inhibitor z-VRPRfmk did not result in increased basal S6 phosphorylation, although it substantially impaired CD3-and CD28-dependent S6 phosphorylation.
The MALT1 inhibitor z-VRPR-fmk partially decreases NF-kB activation in lymphocytes (21) . This compound specifically inhibits the paracaspase activity of MALT1 (while not inhibiting classical caspases), and has provided evidence for the catalytic activity of MALT1, which was previously thought to act solely as an adaptor protein (37) . Our data provide evidence that suggests another function for MALT1 catalytic activity: the activation of mTORC1. Our data showing normal ERK phosphorylation and increased CD69 abundance in z-VRPRtreated cells suggest that this inhibitor does not have nonspecific effects on T cell activation. In addition, we observed no effects of the inhibitor on residual mTOR activation in MALT1-deficient T cells. Furthermore, several studies from the Thome group have reinforced the specificity of z-VRPR for MALT1 (21, 40, 49) .
The mechanism by which the catalytic activity of MALT1 stimulates activation of the signaling pathway that we have characterized here is still unclear, but we hypothesize that there might be additional intermediary molecules that lead to the activation of the mTOR pathway in response to engagement of the TCR and CD28. For example, Kawadler et al. (50) demonstrated the MALT1-mediated cleavage of caspase 8, which leads to lymphocyte proliferation. Because caspase 8 may also be important for p70S6K activity (51), caspase 8 is another potential link between MALT1 and p70S6K activation. In addition, MALT1-mediated cleavage of the proteins A20 and cylindromatosis (CYLD) are implicated in stimulating NF-kB signaling (20, 52) , although neither protein has been implicated in mTOR regulation. A study showed that MALT1 can cleave the protein Regnase-1 (also known as MCPIP1), which normally functions to restrain T cell activation through the destabilization of specific mRNAs, including those that encode several cytokines (53) . Finally, although MALT1 cleaves Bcl10 close to its C terminus, this event appears to promote lymphocyte adhesion, but not NF-kB activation (21) . Thus, MALT1 is not an exclusive stimulator of NF-kB signaling, but participates in other pathways as well.
The major functional connections that we have been able to make thus far between the MALT1-mTOR pathway involve regulation of T cell proliferation and metabolism, but not early activation. The former result is consistent with the finding that primary mouse T cells that have reduced S6 abundance exhibit decreased cellular proliferation, but normal blasting (7) . We also showed that MALT1 activity was dispensable for the CD3-and CD28-stimulated blasting of naïve T cells, as well as for the increased abundance of early activation markers, such as CD69. Thus, there may be a distinction between the homeostatic control of cell size, which appears to require Akt and mTOR signaling (45, 54, 55) , and the more acute, activation-induced increase in cell size that accompanies the proliferation of T cells. The ribosomal protein S6 is a critical regulator of protein translation. It is also one of the main downstream effectors of mTORC1, and as such, it is thought to play a critical role in oncogenesis involving defects within the mTOR signaling cascade (56) (57) (58) . Possible contributions of MALT1 to these pathways will be investigated in future studies.
Our data have also revealed a role for MALT1 in stimulating increased metabolism upon T cell activation, a process important for T cells to meet the changing needs of activated and proliferating T cells (43) . The mTOR pathway is an important regulator of this change (3) . On the basis of our study, we propose that the regulation of metabolism in T cells by MALT1 occurs, at least in part, through mTOR. We also assessed the cell surface abundance of CD71 and CD98, nutrient receptors that facilitate the proliferation of T cells upon activation (59) . We observed increased abundance of both cell surface markers after stimulation; however, treatment with the MALT1 inhibitor did not impair this increase ( fig. S4C ). These data, together with the results from our glycolysis experiments (Fig. 7B) , suggest that the MALT1 inhibitor z-VRPR-fmk does not completely inhibit mTOR activation, and thus, we would not expect to see as potent an effect as that seen with the more direct mTOR inhibitor rapamycin (Fig. 7 ). Numerous reports have described additional important functions for mTOR signaling pathways in the regulation of peripheral T cell differentiation to different effector or regulatory lineages, as well as the regulation of memory T cell development (60, 61) . For example, mTORC1 promotes the development of proinflammatory T H 17 cells, whereas it suppresses the development of anti-inflammatory regulatory T cells. Such effects of mTOR in T cells appear to be mediated, at least in part, through regulation of the metabolic reprogramming that accompanies the activation and proliferation of T cells (62) . Further study is therefore warranted on these aspects of mTOR function as possible additional downstream consequences of signaling from Carma1 and MALT1. 
Cell purification

CD4
+ T cells were separated by MACS (magnetic-activated cell sorting) beads (Miltenyi Biotec) according to the manufacturer's protocol. The purity of the final cell population was >90%.
Antibodies and reagents
Phospho-specific antibodies against ribosomal protein S6 (S235/236 and S240/244), p70 ribosomal protein S6K (T389), mTOR (S2448), PKCq (T538), 4E-BP1 (T70), and phosphorylated substrates of Akt, and Alexa Fluor 647-conjugated antibody against S6 (S235/236 and S240/244) were obtained from Cell Signaling Technology Inc. Antibodies against ribosomal protein S6, 4E-BP1, and mTOR were also obtained from Cell Signaling Technology Inc. Antibodies specific for phosphorylated ERK1/2 (T202/ Y204) were from BD Biosciences. Antibodies specific for MALT1, p70 S6K, and Bcl10 were from Santa Cruz Biotechnology. Antibody specific for Carma1 was obtained from ProSci Inc., whereas antibody against b-actin was from Sigma. Stimulating antibodies, mouse anti-human CD28, hamster anti-mouse CD3 and CD28, phycoerythrin (PE)-conjugated anti-CD69, and phospho-specific antibody against Akt (S473) were obtained from Life Technologies. Fluorescein isothiocyanate (FITC)-conjugated anti-mouse CD71 and PE-conjugated anti-mouse CD98 antibodies were obtained from BioLegend. Horseradish peroxidase (HRP)-conjugated protein A was from GE Healthcare. Antibody specific to the Jurkat cell TCR (C305) was purified from the C305.2 hybridoma (American Type Culture Collection). Biotinconjugated anti-mouse CD3, CD4, and CD28 antibodies were obtained from BD Biosciences. Stimulating antibodies against CD3 and CD28, rabbit antiSyrian hamster immunoglobulin G, and HRP-conjugated donkey antirabbit secondary antibody were obtained from Jackson ImmunoResearch Laboratories Inc. The MALT1 inhibitor z-VRPR-fmk was obtained from A.G. Scientific. Recombinant human TNF-a protein was obtained from R&D Systems. PMA, ionomycin, rapamycin, Akt inhibitor VII (Akti1/2), and IKK inhibitor II (Wedelolactone) were obtained from Calbiochem/EMD. Bisindolylmaleimide VIII acetate was from Enzo Life Sciences. Minimum essential medium (MEM) amino acid solution was from HyClone.
Cells
Jurkat cells, Jurkat cell mutants, including JPM 50.6 cells, MALT1shRNA cells, Bcl10shRNA cells, Carma1shRNA cells, control shRNA cells, and Carma1-reconstituted JPM 50.6 cells, as well as D10 cells (a mouse T cell clone), were maintained as previously described (39, 63, 64) . Human embryonic kidney (HEK) 293T cells were maintained in Dulbecco's MEM supplemented with 10% bovine growth serum (BGS), penicillin, streptomycin, and glutamine.
Flow cytometric analysis
Flow cytometric analysis was performed as previously described (64) . Briefly, cells were starved of serum in phosphate-buffered saline, 1% bovine serum albumin (BSA) for 1 hour at 37°C. Where indicated in the figure legends, cells were also pretreated with the appropriate inhibitors during the starvation period. After stimulation, cells were fixed with 1.5% paraformaldehyde at room temperature and were permeabilized with cold methanol on ice. Cells were then washed three times and incubated with phosphospecific antibodies at room temperature. Samples were processed on a BD LSRII flow cytometer, and data were analyzed with FlowJo software. Where indicated in the figure legends, the "fold increase" of a given protein is defined as the MFI of stimulated cells divided by that of unstimulated cells.
Luciferase assays
Jurkat cells were transfected with 15 mg of NF-kB luciferase reporter plasmid by electroporation and then were cultured in complete medium (RPMI, 5% BGS, containing penicillin and streptomycin) for 16 to 20 hours. Cells were pretreated with vehicle or inhibitor before being stimulated for 6 hours with antibodies against CD3 and CD28, PMA, and ionomycin, or recombinant human TNF-a. Luciferase assays were performed as previously described (25) .
Western blotting analysis and immunoprecipitations
Cells were lysed in NP-40 lysis buffer [1% NP-40, 1 mM EDTA, 20 mM tris-HCl (pH 7.4), 150 mM NaCl] or with radioimmunoprecipitation assay (RIPA) buffer [1% NP-40, 150 mM NaCl, 25 mM tris-HCl (pH 7.6), SDS] for immunoprecipitation before being used for kinase assays. Immunoprecipitations were performed with 20 ml of a 50% slurry of protein G-agarose beads (Millipore). Proteins were resolved by 8 to 10% SDSpolyacrylamide gel electrophoresis and were transferred onto polyvinylidene difluoride membranes, which were then blocked in 4% BSA. The membranes were then incubated with the primary antibodies specified in the figure legends, followed by HRP-conjugated secondary antibodies. Proteins were detected with the SuperSignal West Pico ECL substrate (Thermo Scientific) and imaged on a Kodak Image Station. b-Actin was used as a loading control for Western blotting analysis.
In vitro kinase assays S6K was immunoprecipitated from stimulated Jurkat cells with a specific antibody and protein G beads, and immunoprecipitates were washed with kinase buffer [50 mM Hepes (pH 7.4), 200 mM NaCl, 1% NP-40, and 1 mM EDTA]. After being washed, protein G beads were incubated for 30 min at 30°C in a kinase reaction mix (kinase buffer, GST-S6, and [g- 
Lentiviral transduction and generation of stable cell lines
HEK 293T cells were cotransfected with the pLKO.1 lentiviral vector or the pLEX vector encoding shRNA specific for human Carma1, together with the psPAX2 packaging plasmid and the pMO2.G envelope plasmid with Effectene reagent (Qiagen). Virus-containing culture medium was collected by centrifugation 48 hours later and was used to generate stable cell lines. Jurkat cells were cultured with virus-containing medium and complete medium in a 1:1 ratio, which was replaced with complete medium 24 hours later. To generate cell lines expressing control shRNA, Jurkat cells were transiently transfected with the plasmid pCMV-XL6, which encodes a control shRNA, and placed in selection medium 2 days later. Seeding and selection of positive clones with puromycin (for Carma1shRNA and Carma1-reconstituted JPM 50.6 cells) or G418 (for cell lines expressing control shRNA) was performed as previously described (65) .
Cell number and MTT proliferation assays
The number of viable CD4 + T cells was determined by manual counting and trypan blue exclusion. Primary T cell proliferation was assessed with the CellTiter 96 Aqueous Non-Radioactive Cell Proliferation Assay (Promega). CD4 + T cells were stimulated with antibodies against CD3 and CD28 for the times indicated in the figures, and cells were collected and incubated with substrate for 24 hours at 37°C in a humidified, 5% CO 2 atmosphere. Absorbance was recorded at 490 nm on an enzyme-linked immunosorbent assay plate reader.
Seahorse analysis of T cell respiration
Naïve CD4 + T cells were isolated from C57BL/6 mice, pretreated with z-VRPR-fmk or rapamycin, where indicated, and stimulated for 24 hours in a XF24 cell culture microplate (Seahorse Bioscience). Cells were then analyzed with the Seahorse XF24 Extracellular Flux Analyzer (Seahorse Bioscience) as previously described (66) .
Real-time polymerase chain reaction
RNAs extracted with TRIzol reagent (Invitrogen) were reverse-transcribed to generate complementary DNA (cDNA) with SuperScript III and random primers. Quantitative real-time polymerase chain reaction (RT-PCR) assays were performed with Mastercycler realplex and SYBR Green Master Mix (Eppendorf ). The abundance of EIF4EBP1 mRNA (encoding 4E-BP1) was normalized to that of ACTB mRNA (encoding b-actin), as calculated with the 2 −DDC T method. The primers used were as follows: EIF4EBP1 forward, 5′-GCGCAATAGCCCAGAAGATA-3′; EIF4EBP1 reverse, 5′-CCCTTGGTAGTGCTCCACAC-3′; b-actin forward, 5′-TGTCCACCTTCCAGCAGATGT-3′; b-actin reverse, 5′-AGCTCAGTAACAGTCCGCCTAGA-3′.
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